Sanofi Pasteur Inc.
Sanofi Pasteur Inc. is a foreign-owned, for-profit pharmaceutical manufacturer specializing in vaccines and medical supplies, registered in the System for Award Management (SAM) since 2002. Located in Swiftwater, Pennsylvania, the company is a major global supplier of vaccines and medical countermeasures to various U.S. federal government agencies. As a leading vaccine manufacturer, Sanofi Pasteur provides a comprehensive range of immunization products, including seasonal and pandemic influenza vaccines, pediatric vaccines, adult vaccines, and other critical public health immunizations to federal agencies such as the Centers for Disease Control and Prevention, Department of Veterans Affairs, Department of Defense, and Department of Health and Human Services.
Through its federal contract awards, Sanofi Pasteur Inc. has consistently provided a diverse array of medical products, with a primary focus on vaccines. The company's contract awards span multiple vaccine categories, including influenza vaccines (seasonal and pre-pandemic), respiratory syncytial virus (RSV) vaccines, meningococcal vaccines, yellow fever vaccines, and vaccines for children and adults. These contracts have been awarded by agencies like the Indian Health Service, Bureau of Prisons, Department of State, and Defense Logistics Agency, covering a wide range of public health needs. The contracts are typically firm fixed price and do not utilize set-aside designations, reflecting the company's competitive position in the federal marketplace. Contract values range from relatively small purchases of a few thousand dollars to large-scale awards exceeding $79 million, demonstrating Sanofi Pasteur's capability to meet varied government vaccine procurement requirements.
Sanofi Pasteur Inc. holds multiple significant Indefinite Delivery Contracts (IDVs) across various federal agencies. The company has secured several notable IDVs, including a $1.99 billion contract with the CDC for Vaccines for Children (VFC) program, a $47.55 million influenza vaccine contract with the Department of Veterans Affairs, and multiple CDC contracts for adult and pediatric flu vaccines totaling hundreds of millions of dollars. These IDVs cover vaccine procurement for multiple fiscal years, typically ranging from one to five years, and support critical public health initiatives across federal, state, and tribal healthcare systems. The IDVs enable streamlined procurement of vaccines for different populations, including pediatric, adult, and senior populations, and span diverse vaccine types such as influenza, measles, mumps, rubella, hepatitis, pneumococcal, and meningococcal vaccines. The contracts are predominantly multiple-award or single-award vehicles, allowing flexible ordering of vaccines to support national immunization programs and emergency preparedness efforts.
NCXBGGQ8YTU9 325414
Not listed 1 Discovery Dr, Swiftwater, PA 18370, USA
1/2/02 11/1/25 Seqirus Inc.
Seqirus Inc., a division of the global biotechnology company CSL Seqirus, is a leading provider of medical countermeasures, vaccines, and related products for pandemic preparedness and response to the U.S. federal government. Registered in SAM.gov since February 2016, the company is a foreign-owned, for-profit organization with a state-of-the-art manufacturing facility located in Holly Springs, North Carolina. Seqirus specializes in developing and producing vaccines, particularly focusing on influenza and emerging infectious disease preparedness, working closely with federal agencies to maintain critical medical stockpiles and support public health emergency response capabilities.
The company has been awarded multiple federal contracts primarily with the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR), focusing on acquiring, producing, storing, and testing various medical countermeasures. These contracts have included procuring influenza vaccine candidates, conducting clinical trials, producing bulk vaccine lots, storing and maintaining pre-pandemic vaccine stockpiles, and developing seed lots for specific influenza strains like H5N8 and H2Nx. The contracts consistently involve firm fixed-price delivery orders with no specific set-aside designations, ranging from small-scale research and compatibility studies to large-scale vaccine production efforts. Seqirus has demonstrated expertise in handling complex medical countermeasure requirements, including physical and chemical compatibility studies, antigen storage and stability testing, and vaccine development for potential pandemic scenarios.
Seqirus holds a significant $13.4 billion Indefinite Delivery Contract (IDC) with HHS ASPR, awarded on February 22, 2022, with an ultimate completion date of February 21, 2025. This single-award contract serves as the primary mechanism for the company's federal contracting activities, enabling rapid procurement of medical countermeasures. Under this IDC, HHS ASPR has issued numerous task orders totaling over $116 million, covering a wide range of services such as vaccine production, antigen procurement, clinical research, and stockpile maintenance. The contract's broad scope allows Seqirus to provide flexible and comprehensive support for pandemic preparedness, including the acquisition of medical countermeasures like vaccines and adjuvants, production of specific influenza strains, and conducting specialized research to support national health security initiatives.
Z6N1LJ2RD6E3 325414
Not listed 475 Green Oaks Pkwy, Holly Springs, NC 27540, USA
2/5/16 11/15/25 Medimmune LLC
--
PHXNKFPB76E7 325414
Not listed Medimmune Way, Gaithersburg, MD 20878, USA
7/3/01 9/25/25 Glaxosmithkline, LLC
Glaxosmithkline, LLC, doing business as Glaxosmithkline, is a foreign-owned, for-profit pharmaceutical company registered in the U.S. federal government's System for Award Management (SAM). The company provides a comprehensive range of pharmaceutical products, with a primary focus on vaccines, antiviral medications, and other medical countermeasures to federal agencies. As a global pharmaceutical enterprise, Glaxosmithkline develops, manufactures, and distributes critical medical products across various therapeutic areas, specializing in vaccines, respiratory medicines, and infectious disease treatments.
Through federal contract awards, Glaxosmithkline has consistently delivered pharmaceutical goods and services to multiple government agencies, including the Departments of Justice, Veterans Affairs, Defense, Health and Human Services, and State. The company's contract work predominantly involves supplying influenza vaccines to federal correctional institutions, military facilities, and healthcare systems. Notably, Glaxosmithkline has been awarded numerous delivery order contracts for flu vaccines, ranging from small orders of a few thousand dollars to larger contracts exceeding $500,000. These contracts are typically not set aside for specific business types and span various federal agencies, including the Bureau of Prisons, Veterans Health Administration, and Indian Health Service. The company has also provided antiviral medications like zanamivir and participated in specialized pharmaceutical development projects, such as fill/finish activities for COVID-19 vaccine adjuvants.
In terms of federal grant awards, Glaxosmithkline has been involved in targeted research efforts, with a notable subaward from Boston University focused on developing a small molecule drug to treat urinary tract infections. Specifically, the grant supported research on a FimH antagonist targeting E. coli bacteria, aimed at preventing bacterial binding to the bladder wall. This research project emphasized early clinical development, exploring the safety, tolerability, and pharmacokinetics of the potential treatment, with goals of facilitating scale-up of active pharmaceutical ingredient manufacturing and drug product development for future clinical studies.
Glaxosmithkline holds multiple significant federal Indefinite Delivery Contracts (IDVs), particularly with the Centers for Disease Control and Prevention (CDC) and the Department of Veterans Affairs. These IDVs cover a wide range of vaccine procurement, including pediatric and adult vaccination programs. The CDC IDVs are substantial, with contracts valued up to $1.35 billion for pediatric vaccines and $182 million for pediatric flu vaccines. The company also holds a Federal Supply Schedule contract with a maximum ceiling of $3.9 billion, covering pharmaceutical products and medical supplies. These IDVs support critical national immunization efforts, allowing federal agencies to place task orders for vaccines with specific quantities and delivery requirements. The contracts typically span multiple years and provide flexible procurement mechanisms for government health initiatives, with most being multiple-award contracts that do not have specific set-aside designations.
FRHTPHMZMX47 325412
Not listed 410 Blackwell St, Durham, NC 27701, USA
10/25/10 1/15/26 Seqirus USA Inc.
Seqirus USA Inc. is a global biotechnology company specializing in the development, manufacturing, and delivery of influenza vaccines to various federal government agencies. As a foreign-owned, for-profit organization registered in the SAM.gov system, the company provides critical vaccine solutions to multiple federal healthcare programs. Headquartered in Summit, New Jersey, Seqirus USA Inc. has been a registered federal contractor since May 15, 2008, with its current registration valid through November 24, 2025, and focuses on producing a range of influenza vaccine formulations for pediatric, adult, and elderly populations.
Through its federal contract awards, Seqirus USA Inc. has consistently supplied influenza vaccines to numerous federal agencies, including the Department of Veterans Affairs, Department of Defense, Department of Justice Bureau of Prisons, Department of Health and Human Services, and the Indian Health Service. The majority of its contracts are firm-fixed-price delivery orders and purchase orders for flu vaccines, ranging from $745 to over $9 million. These contracts cover vaccine delivery to various federal facilities such as VA medical centers, federal correctional institutions, and military healthcare centers. Notably, most of these contract awards do not utilize set-aside designations, indicating Seqirus's competitive capabilities in the federal marketplace. The company provides multiple vaccine types, including quadrivalent vaccines, multi-dose vials, pre-filled syringes, and specialized high-dose vaccines for individuals 65 and older.
Seqirus USA Inc. holds several significant Indefinite Delivery Contracts (IDCs) across federal agencies, including a $51.6 million single-award IDC with the VA National Acquisition Center for the 2025-2026 flu season, multiple IDCs with the Centers for Disease Control and Prevention valued at over $410 million for pediatric and adult flu vaccines, and a $36.1 million IDC with the Defense Logistics Agency's Medical Supply Chain. These IDCs allow federal agencies to place task orders for specific vaccine quantities and presentations, supporting annual flu vaccination programs for military personnel, veterans, federal inmates, and other government-served populations. The contracts cover various vaccine formulations and are typically multi-award vehicles with performance periods ranging from one to five years, demonstrating Seqirus's strategic importance in federal immunization efforts.
N6U7P2B9VHS5 325414
Not listed 25 Deforest Ave #200, Summit, NJ 07901, USA
5/15/08 11/24/25